个人简介

赵洪友博士长期从事新型医用光敏药物的研发和临床前评价，激光诊疗设备的研发以及光动力治疗肿瘤的机制研究。由顾瑛院士牵头，赵洪友博士主要负责的国内第一个新型二氢卟吩类光敏药物KAE已经完成临床前功能与安全性评价，即将开展临床试验。参与研发的 “倍频Nd：YV04激光光动力治疗仪” 已获国家食品药品监督管理局三类医疗器械认证（国食药监械(准)字2013第3240155号），光学相干成像仪已获北京食品药品监督管理局二类器械认证（京食药监械(准)字2014第2241232号）。以第一/通讯作者在国际医学期刊 Eur. J. Cancer （Q1; IF=9.162）发表封面文章1篇；国际医用化学期刊 J. Med. Chem. （Q1; IF=7.446）J Mater. Chem. B (Q1; IF=6.331) 发表研究论文多篇。在国际生物光子学期刊J. Photochem. and Photobio. B（IF=6.252）, Photodiagnosis Photodyn. Ther.（IF=3.631）等杂志发表论文多篇。

教育/培训经历

2011. 09-2014. 07 解放军总医院 激光医学 博士研究生

2008. 09-2011. 07 华南师范大学 生物医学光子学 硕士研究生

2004. 09-2008. 07  内蒙古大学  生物学  本科

工作经历

2020.01-现在 北京理工大学，威廉希尔， 特别副研究员

2016.09-2019. 03 美国路易斯安那州州立大学，癌症研究中心,  博士后

2014.08-2016. 08 美国南阿拉巴马大学，米切尔癌症研究中心， 博士后

学术任职

中华医学会激光医学分会委员；北京医学会激光医学分会委员；同时还担任J. Photochem. and Photobio. B, Photodiagnosis Photodyn. Ther.等多个国际学术期刊审稿人。

研究领域

可逆光酸治疗肿瘤的机制研究

新型光敏剂的研发以及生物功能特性研究

无创光疗治疗阿尔茨海默症的谱效与量效关系研究

讲授课程

为研究生讲授《生物医学光子学与应用》课程

参与项目

[1] 武汉光电国家研究中心开放基金，省部级课题，1870037222101，光治疗创伤后应激障碍的基础研究及其机制探索，2021-01至2023-12，12万元，在研，主持

[2] 青年教师学术启动计划，学校项目，1870011182003，LED治疗阿尔兹海默症的量效关系和机制研究，2020-01至2022-12，40万元，在研，主持

[3] 公司委托技术开发任务，横向项目，201925141023，KAE新药用于光动力治疗CIN临床前药效学评测研究，2020-01至2022-12，147.126万元，在研，主要负责

[4] 国家自然科学基金委员会, 面上项目，61475194，光动力疗法对活化T细胞行为调控及效应机制研究，2015-01至2018-12, 72万元，参与

[5] 国家自然科学基金委员会, 面上项目，61308117，线粒体靶向竹红菌素光动力治疗脉络膜新生血管的实验研究，2013-01至2016-12，66万元，参与

SCI Journal paper

[1] Hongyou Zhao*, Haolin Liu, Lin Kang, Tianzhen Sun, Yidi Liu, Defu Chen and Ying Gu* et al. In vitro and in vivo evaluation of a chlorin-based photosensitizer KAE® for cancer treatment. Photodiagnosis Photodyn Ther. 2022. doi: https://doi.org/10.1016/j. pdpdt.

[2] Hongyou Zhao, Tengda Ji, Tianzhen Sun, Haolin Liu, Yidi Liu, Haixia Qiu and Ying Gu* et al. “Comparative study on photobiomodulation between 630 nm and 810 nm LED in diabetic wound healing both in vitro and in vivo” J. Innov. Opt. Heal. Sci. 2022. 15: 2250010-1-2250010-10.

[3] Hongyou Zhao, Yi Bin, Zhipin Liang, Adam I. Riker, and Yaguang Xi* et al. “Cyclin G2, a novel target of sulindac to inhibit cell cycle progression in colorectal cancer” Genes & Diseases. 2021. 8: 320-330.

[4] Li-Peng Zhang, Xianqiang Li, Hongyou Zhao*, Lin Kang Tianlong Liu and Yuxia Zhao* et al. “Ultra-high photoactive thiadiazolo [3,4-g] quinoxaline nanoparticles with active-targeting capability for deep photodynamic therapy” J. Mater. Chem. B. 2021. 9: 8330–8340.

[5] Hongyou Zhao, Rong Yin, Ying Wang, Ying Gu* et al. Modulating mitochondrial morphology enhances antitumor effect of 5-ALA-mediated photodynamic therapy both in vitro and in vivo. J. Photochem. and Photobio. B. 2017. 176: 81-91.

[6] Qianli Zou#, Hongyou Zhao#, Yuxia Zhao, Ying Gu*, et al. Effective Two-Photon Excited Photodynamic Therapy of Xenograft Tumors Sensitized by Water-Soluble Bis(arylidene)cycloalkanone Photosensitizers. J. Med. Chem. 2015, 58:7949−7958.

[7] Hongyou Zhao, Rong Yin, Ying Wang, Ying Gu* et al. In vitro and in vivo antitumor activity of a novel hypocrellin B derivative for photodynamic therapy. Photodiagnosis Photodyn. Ther. 2014, 11: 204-212.

[8] Hongyou Zhao, Yucheng Wang, Haixia Qiu, Ying Gu*. 2014. Photodynamic therapy and anti-tumor immunity. Chinese Journal of Laser Medicine & Surgery, 2014, 23:34-38.

[9] Hongyou Zhao, Qun Chen, Da Xing*. 2011. New insights of mitochondria reactive oxygen species generation and cell apoptosis induced by low dose photodynamic therapy. Eur. J. Cancer, 2011, 47：2750-2761.

EI Journal paper

[1] Hongyou Zhao, Bin Yi, Ruixia Ma and Yaguang Xi. MiR-182 is involved in sulindac anticancer activity in colon cancer. 2017 AACR Annual Meeting: Research Propelling Cancer Prevention and Cures. Washington, D.C

[2] Hongyou Zhao, Bin Yi, Hong Chang, Zhipin Liang, Ruixia Ma and Yaguang Xi. Sulindac inhibition of colon tumor cell growth through miR-182/FOXO3a/CyclinG2 signaling. 2016 AACR Precision Medicine Series: Cancer Cell Cycle-Tumor Progression and Therapeutic Response. Orlando FL.

[3] Hongyou Zhao, Jie Ren, Rong Yin, Ying Wang, Ying Gu. The mechanism of apoptosis induced by photodynamic therapy. 2012 SPIE-Photonics Asia Meeting. Beijing.

中文论文

[1] 刘浩林，邱海霞，曾晶，赵洪友*，顾瑛* 新型二氢卟吩类光敏剂KAE介导的光动力疗法对HeLa细胞的杀伤作用，激光医学杂志，2022 DOI：10.13480/j.issn1003-9430.2021.0301

[2] 赵洪友；王钰铖；邱海霞；顾瑛* 光动力治疗与抗肿瘤免疫， 激光医学杂志，2 014,23,34-38

申请专利

[1] 布鲁氏杆菌的检测试剂盒与检测方法，发明人：姚杰，赵洪友，程诚，2021-02-05，专利号：CN112322764A

[2] 叶酸代谢相关分子标志物基因突变的检测试剂盒与检测方法，发明人：姚杰，赵洪友，程诚，2021-03-19，专利号：CN112522375A

[3] 一种基于积分球效应的光动力治疗器械,  发明人：顾瑛，孙圣坤，谭一舟，邱海霞，陈德福，赵洪友，曾晶，王颖，2020-11-8, 专利号：ZL202011295644.X.

[4] 一种新型光动力治疗器械，发明人：邱海霞，顾瑛，孟元光，谭一舟，陈德福，赵洪友，王颖，曾晶，2020-10-20, 专利号：ZL202011295666.6.

[5] 二氢卟酚e6三葡甲胺盐在光动力治疗宫颈癌及癌前病变中的应用，发明人：顾瑛，庞玉华，吴思丹，赵洪友，宋治国，2021-08-27，申请号：CN202110631058.6

Personal Resume

Dr. Zhao has long been working in the research, development and preclinical evaluation of novel medical photosensitive drugs, the research and development of laser diagnosis and treatment equipment, and the mechanism research of photodynamic therapy of tumors. Led by Academician Gu and Dr. Zhao is mainly responsible for the first domestic new type of chlorin photosensitive drug KAE has been completed preclinical function and safety evaluation, and will start clinical trials soon. The frequency-doubling Nd: YV04 laser photodynamic therapy instrument that participated in the research and development has been certified by the State Food and Drug Administration for Class III medical devices (SFDA 2013 No. 3240155), and the optical coherent imager has been approved by Beijing Food and Drug Administration Class II device certification (Beijing Food and Drug Administration 2014 No. 2241232). As the first/corresponding author published 1 cover article in the international medical journal Eur. J. Cancer (Q1; IF=9.162); several research papers in the international medical chemistry journal J. Med. Chem. (Q1; IF=7.446); J Mater Chem B (Q1; IF=6.331); several research papers in the International Journal of Biophotonics J. Photochem. and Photobio. B: (IF=6.252), Photodiagnosis Photodyn. Ther. (IF=3.631).

Education Background

2011-2014, Doctor of Medicine; Medical School of Chinese PLA, China; Laser Medicine

2008-2011, Master of Biophysics; South China Normal University, China; Biophotonics

2014-2008, Bachelor of Bioscience; Inner Mongolia University, China; Life Science.

Positions and Employment

2020.01-now; Assistant Professor; Institute of Engineering Medicine, Beijing Institute of Technology

2016.8-2019.4; Postdoctoral Fellow; Department of Genetics, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center

2014.8-2016.7; Postdoctoral Fellow; Mitchell Cancer Institute, University of South Alabama

Professional Membership/Academic Appointments

Associate member, Laser Medicine branch of Chinese Medical Association

Associate member, Laser Medicine branch of Beijing Medical Association

Associate member, American Association for Cancer Research

Research and Teaching Interest

Research on the mechanism of reversible photoacid treatment of tumors;

Research and development of new photosensitizers and preclinical systematic reviews;

The relationship between spectrum effect and dose effect of non-invasive phototherapy for Alzheimer's disease.